Search results for "colon cancer"

showing 10 items of 157 documents

Update on capecitabine alone and in combination regimens in colorectal cancer patients

2010

Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients. © 2010 Elsevier Ltd.

OncologyOrganoplatinum CompoundsOxaloacetatesSettore MED/06 - Oncologia MedicaColorectal cancerLeucovorinCetuximabAdministration OralDeoxycytidineAntineoplastic Combined Chemotherapy ProtocolsProdrugsAdjuvantCetuximabAntibodies MonoclonalGeneral MedicineNeoadjuvant TherapyOxaliplatinBevacizumabColorectal carcinomacolon cancerOncologyTolerabilityChemotherapy AdjuvantMetastaticFluorouracilNeoadjuvantColorectal Neoplasmsmedicine.drugDiarrheaAntimetabolites Antineoplasticmedicine.medical_specialtyBevacizumabAntibodies Monoclonal HumanizedIrinotecanDrug Administration ScheduleAdjuvant; Bevacizumab; Capecitabine; Cetuximab; Colorectal carcinoma; Irinotecan; Metastatic; Neoadjuvant; Oxaliplatin; Radiotherapy; Oncology; Radiology Nuclear Medicine and ImagingCapecitabineInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingCapecitabineRadiotherapybusiness.industrymedicine.diseaseOxaliplatinClinical trialIrinotecanCamptothecinRadiotherapy AdjuvantbusinessCancer Treatment Reviews
researchProduct

Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders

2021

OncologyPeritoneal metastasismedicine.medical_specialtyColonic NeoplasmStagingColorectal cancerbusiness.industryConfoundingGeneral Medicinemedicine.diseaseColon cancerPeritoneal invasionOncologyTumour cellHomogeneousInternal medicinemedicineLocal recurrencePeritoneal metastasiSurgeryPeritoneumbusinessPeritoneal NeoplasmsHuman
researchProduct

Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting

2013

Abstract: The modern approach for metastatic colorectal cancer (mCRC) patients is based on the identification of oncogenic pathways, which could be targeted by specific molecules. Vascular endothelial growth factor (VEGF)- and epithelial growth factor receptor (EGFR)-related pathways represent the most important biological mechanisms for cancer development and progression. However, the most significant results by VEGF and EGFR targeting could be achieved through the combination of these drugs with standard chemotherapeutic regimens. These strategies aim to improve the resectability of liver and lung metastases. For those patients who cannot be eligible for metastases resection, a 'continuum…

OncologyVascular Endothelial Growth Factor Amedicine.medical_specialtyColorectal cancerSettore MED/06 - Oncologia MedicaVEGF receptorsClinical BiochemistryResectionchemistry.chemical_compoundGrowth factor receptorInternal medicineDrug DiscoveryMedicineHumansTarget therapyContinuum of carePharmacologybiologybusiness.industryPharmacology. Therapycolon cancer EGFR target therapies VEGFmedicine.diseaseVascular endothelial growth factorErbB Receptorschemistrybiology.proteinMolecular MedicineCancer developmentbusinessColorectal Neoplasms
researchProduct

33 EFFECT OF miR-21, miR-182 AND let-7i ON TSP-1 EXPRESSION IN COLON CANCER CELL LINE

2010

Oncologybusiness.industryColon cancer cell lineCancer researchMedicineRadiology Nuclear Medicine and imagingGeneral MedicinebusinessCancer Treatment Reviews
researchProduct

Efficacy of zoledronic acid in patients with colorectal cancer metastatic to bone

2011

Oncologymedicine.medical_specialtyHistologyPhysiologybusiness.industryColorectal cancerEndocrinology Diabetes and MetabolismBone metastasismedicine.diseaseZoledronic acidInternal medicinemedicineIn patientbusinessmedicine.drugMetastatic colon cancerBone
researchProduct

Novel P53 mutations detected by FAMA in colorectal cancers

2006

Background The aim of the study was to identify p53 gene mutations by FAMA (fluorescence-assisted mismatch analysis) in colorectal cancers. Patients and methods Analytical scanning of the p53 gene (exons 5–9) was performed in colon cancer samples from 44 consecutive patients by FAMA. FAMA is a semiautomatic scanning approach based on the chemical cleavage of the mismatch in fluorescently labeled heteroduplex DNA, obtained from the combination of a normal and a mutated allele. FAMA has already shown optimal levels of diagnostic accuracy and sensitivity in detecting gene mutations (nucleotide substitutions, insertions/deletions) both at the germline and somatic level. The peculiar feature of …

Oncologymedicine.medical_specialtyMutantDNA Mutational AnalysisMutation MissenseGene mutationmedicine.disease_causeExonInternal medicinemedicineMissense mutationHumansKey words: colon cancer p53 mutations FAMAAlleleGeneMutationbusiness.industryHematologyDNA NeoplasmExonsGenes p53Molecular biologyOncologybusinessColorectal NeoplasmsHeteroduplex
researchProduct

27. Differences in adjuvant chemotherapy administration for stage II colon cancer patients – a EURECCA international comparison

2014

Oncologymedicine.medical_specialtyOncologybusiness.industryAdjuvant chemotherapyInternal medicinemedicineSurgeryGeneral MedicinebusinessAdministration (government)Stage ii colon cancerEuropean Journal of Surgical Oncology (EJSO)
researchProduct

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE…

2021

International audience; Aim Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon cancer (CC) but its effect on oncological outcomes is uncertain. The aim of the present paper was to report 3-year oncological outcomes, representing the secondary endpoints of the PRODIGE 22 trial. Method PRODIGE 22 was a randomized multicentre phase II trial in high-risk T3, T4 and/or N2 CC patients on CT scan. Patients were randomized between 6 months of adjuvant FOLFOX (upfront surgery) or perioperative FOLFOX (four cycles before surgery and eight cycles after; FOLFOX perioperative). In wild-type RAS patients, a third arm testing perioperative FOLFOX-cetuximab was added. The pri…

Oncologymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancer[SDV]Life Sciences [q-bio]medicine.medical_treatmentPopulationLeucovorinsurvival03 medical and health sciences0302 clinical medicineFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumanseducationNeoplasm StagingColectomyeducation.field_of_studybusiness.industryHazard ratioGastroenterologyPerioperativecolectomyPrognosisInterim analysismedicine.diseaseNeoadjuvant Therapydigestive system diseasescolon cancerChemotherapy Adjuvant030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologyFluorouracilNeoplasm Recurrence Localbusinessneoadjuvant chemotherapyFollow-Up Studiesmedicine.drugColorectal Disease
researchProduct

S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Pati…

2021

<b><i>Background:</i></b> Fatigue is a common distressing symptom for patients living with chronic or acute diseases, including liver disorders and cancer (<i>Cancer-Related Fatigue</i>, CRF). Its etiology is multifactorial, and some hypotheses regarding the pathogenesis are summarized, with possible shared mechanisms both in cancer and in chronic liver diseases. A deal of work has investigated the role of a multifunctional molecule in improving symptoms and outcomes in different liver dysfunctions and associated symptoms, including chronic fatigue: S-adenosylmethionine (SAM; AdoMet). The aim of this work is actually to consider its role also in oncologic…

Oncologymedicine.medical_specialtyS-AdenosylmethionineBevacizumabCancer-related fatigueColorectal cancerAdoMetFOLFOXInternal medicineSurveys and QuestionnairesDrug DiscoverymedicineHumansPharmacology (medical)Cancer-related fatigueFatiguePharmacologybusiness.industryCancerChronic fatigueGeneral Medicinemedicine.diseaseCancer treatment toxicityOxaliplatinColon cancerOxaliplatinRegimenInfectious DiseasesOncologyFunctional Assessment of Chronic Illnesses Therapy-FatigueColonic NeoplasmsDietary SupplementsQuality of Lifemedicine.symptombusinessmedicine.drugChemotherapy
researchProduct

Colon cancer cell-derived exosomes modulate macrophage immunosuppressive phenotype associated to PD-L1 expression

PD-L1TAMSettore BIO/13 - Biologia Applicatatumor-derived exosomeColon cancer
researchProduct